162 related articles for article (PubMed ID: 19487444)
41. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.
Flamm RK; Rhomberg PR; Kaplan N; Jones RN; Farrell DJ
Antimicrob Agents Chemother; 2015 May; 59(5):2583-7. PubMed ID: 25691627
[TBL] [Abstract][Full Text] [Related]
42. Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.
Mistry TL; Truong L; Ghosh AK; Johnson ME; Mehboob S
ACS Infect Dis; 2017 Jan; 3(1):54-61. PubMed ID: 27756129
[TBL] [Abstract][Full Text] [Related]
43. A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
Kwon J; Mistry T; Ren J; Johnson ME; Mehboob S
Bioorg Med Chem; 2018 Jan; 26(1):65-76. PubMed ID: 29162308
[TBL] [Abstract][Full Text] [Related]
44. 2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI.
Ramnauth J; Surman MD; Sampson PB; Forrest B; Wilson J; Freeman E; Manning DD; Martin F; Toro A; Domagala M; Awrey DE; Bardouniotis E; Kaplan N; Berman J; Pauls HW
Bioorg Med Chem Lett; 2009 Sep; 19(18):5359-62. PubMed ID: 19682900
[TBL] [Abstract][Full Text] [Related]
45. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
[TBL] [Abstract][Full Text] [Related]
46. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
Miller WH; Seefeld MA; Newlander KA; Uzinskas IN; Burgess WJ; Heerding DA; Yuan CC; Head MS; Payne DJ; Rittenhouse SF; Moore TD; Pearson SC; Berry V; DeWolf WE; Keller PM; Polizzi BJ; Qiu X; Janson CA; Huffman WF
J Med Chem; 2002 Jul; 45(15):3246-56. PubMed ID: 12109908
[TBL] [Abstract][Full Text] [Related]
47. Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Critchley IA; Karlowsky JA; Draghi DC; Jones ME; Thornsberry C; Murfitt K; Sahm DF
Antimicrob Agents Chemother; 2002 Feb; 46(2):550-5. PubMed ID: 11796376
[TBL] [Abstract][Full Text] [Related]
48. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa.
Cotton MF; Wasserman E; Smit J; Whitelaw A; Zar HJ
BMC Infect Dis; 2008 Apr; 8():40. PubMed ID: 18380900
[TBL] [Abstract][Full Text] [Related]
49. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
50. Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.
Yao J; Abdelrahman YM; Robertson RM; Cox JV; Belland RJ; White SW; Rock CO
J Biol Chem; 2014 Aug; 289(32):22365-76. PubMed ID: 24958721
[TBL] [Abstract][Full Text] [Related]
51. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
[TBL] [Abstract][Full Text] [Related]
52. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
[TBL] [Abstract][Full Text] [Related]
53. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Karlowsky JA; Nichol K; Zhanel GG
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
[TBL] [Abstract][Full Text] [Related]
54. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
55. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
56. Methyl-branched fatty acids, inhibitors of enoyl-ACP reductase with antibacterial activity from Streptomyces sp. A251.
Zheng CJ; Sohn MJ; Chi SW; Kim WG
J Microbiol Biotechnol; 2010 May; 20(5):875-80. PubMed ID: 20519910
[TBL] [Abstract][Full Text] [Related]
57. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).
Sampson PB; Picard C; Handerson S; McGrath TE; Domagala M; Leeson A; Romanov V; Awrey DE; Thambipillai D; Bardouniotis E; Kaplan N; Berman JM; Pauls HW
Bioorg Med Chem Lett; 2009 Sep; 19(18):5355-8. PubMed ID: 19682901
[TBL] [Abstract][Full Text] [Related]
58. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.
Kitagawa H; Kumura K; Takahata S; Iida M; Atsumi K
Bioorg Med Chem; 2007 Jan; 15(2):1106-16. PubMed ID: 17095231
[TBL] [Abstract][Full Text] [Related]
59. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
60. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
